{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:21:59Z","timestamp":1788906119299,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>The chemotherapy response score (CRS) is used to score histopathologic response to neoadjuvant chemotherapy (NACT) of patients with extrauterine high-grade serous carcinoma. This study was undertaken to determine if the CRS in the omentum, adnexa or when combined correlates with (1) progression-free survival (PFS) or overall survival (OS), (2) laparoscopic score of abdominal disease, (3) Cancer antigen 125 levels, (4) BRCA status, and (5) platinum-resistant disease. A total of 158 cases were retrospectively collected that received NACT between April 2013 and February 2018 at a single institution. The 3-tier B\u00f6hm CRS system was applied to the omentum and adnexa. Survival outcomes between scored subgroups were analyzed using Cox proportional hazards regression. Spearman rank correlation analyses were used to assess CRS and clinical data. A total of 119 cases were treated only with carboplatin\/paclitaxel. Omental CRS was: 1 (23 cases, 19.3%), 2 (65 cases, 54.6%), and 3 (31 cases, 26.1%), whereas adnexal CRS was: 1 (50 cases, 42%), 2 (48 cases, 40.3%) and 3 (21 cases, 17.6%). The omental CRS was significantly associated with PFS as a 2-tier score (hazard ratio [HR]=0.612, 95% confidence interval [CI]: 0.378-0.989, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.045) but not associated with the PFS using the 3-tier score or with OS using either system. Adnexal CRS was not associated with OS but was significantly associated with PFS using the 3-tier (HR=0.49, 95% CI: 0.263-0.914, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.025) and 2-tier scores (HR=0.535, 95% CI: 0.297-0.963, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.037). The combined score was not associated with OS but was significantly associated with PFS using the 3-tier (HR=0.348, 95% CI: 0.137-0.88, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.026) and 2-tier scores (HR=0.364, 95% CI: 0.148-0.896, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.028). No CRS system used associated with laparoscopic assessment of disease. CRS in the omentum had no significant association with platinum resistance; however, the adnexal CRS 1\/2 were 3 times as likely to develop platinum resistance compared with CRS 3 (relative risk=3.94, 95% CI: 1.03-15.09, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.046). The CRS, when used on the omentum, adnexa, and as a combined score, was significantly associated with PFS but not with OS. Adnexal CRS 1\/2 are more likely to develop platinum-resistant disease. Therefore, the use of this pathology parameter may be useful for clinical management.<\/jats:p>","DOI":"10.1097\/pas.0000000000001391","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:12:05Z","timestamp":1571854325000},"page":"206-213","source":"Crossref","is-referenced-by-count":30,"title":["A 3-Tier Chemotherapy Response Score for Ovarian\/Fallopian Tube\/Peritoneal High-grade Serous Carcinoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Barrett C.","family":"Lawson","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Euscher","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetha","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanPing","family":"Zhong","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Department of Pathology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Fleming","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarain high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PGP.0000000000000307","article-title":"The chemotherapy response score (CRS): interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in tuboovarian high-grade serous carcinoma","volume":"36","author":"Said","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3802\/jgo.2017.28.e73","article-title":"External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2018.08.042","article-title":"Prognostic implications of histological tumor regression (B\u00f6hm\u2019s score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal and ovarian carcinoma","volume":"151","author":"Rajkumar","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ijgc-2018-000092","article-title":"Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated chemotherapy response score (CRS) results","volume":"29","author":"B\u00f6hm","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/IGC.0000000000000945","article-title":"Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma","volume":"27","author":"Coghlan","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/IGC.0000000000001366","article-title":"Prognostic value of pathologic chemotherapy response score in patients with ovarian cancer after neoadjuvant chemotherapy","volume":"28","author":"Michaan","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ijgc-2019-000222","article-title":"Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score","volume":"29","author":"McNulty","year":"2019","journal-title":"Int J Gynecol Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:56:51Z","timestamp":1695423411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001391"}},"subtitle":["Is it Clinically Relevant?"],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001391","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,22]]}}}